The glycoprotein Ilb-llla complex (GP Ilb-llla) is a multifunctional transmembrane protein on platelets. Its most completely described function is as a fibrinogen receptor that mediates platelet aggregation, but it is also involved in clot retraction, signal transduction, calcium transport, and other events. However, the mechanisms that regulate the functions of GP Ilb-llla during platelet activation are largely unknown. One possible mechanism is phosphorylation, since several other receptors are regulated by this process. We found that GP Illa, but not GP Ilb, was phosphorylated in 32P-labeled platelets, predominantly on threonine residues. Furthermore, GP llla phosphorylation increased four-LYCOPROTEINS IIb AND IIIa are abundant inte-G gral membrane proteins on platelets that exist as Ca2+-dependent heterodimer complexes, termed glycoprotein (GP) IIb-IIIa.'~* Glycoprotein IIb, the a-subunit (molecular weight [mol wt] -140,000), consists of a heavy chain (mol wt -120,000) disulfide-linked to a light chain (mol wt = 25,000); G P IIIa, the @-subunit, is a single polypeptide of mol wt i~ 105,000.2 Recent cloning and sequencing studies have established that G P IIb-IIIa is a member of a large family of adhesive receptors, the integrins (reviewed in reference 3). These studies also predict that G P IIIa and the light chain of G P IIb each contain a membrane-spanning region near its carboxy t e r m i n~s ,~.~ a short cytoplasmic domain (20 and 41 amino acids, respectively), and a much larger extracellular component.
(mol wt -120,000) disulfide-linked to a light chain (mol wt = 25,000); G P IIIa, the @-subunit, is a single polypeptide of mol wt i~ 105,000.2 Recent cloning and sequencing studies have established that G P IIb-IIIa is a member of a large family of adhesive receptors, the integrins (reviewed in reference 3). These studies also predict that G P IIIa and the light chain of G P IIb each contain a membrane-spanning region near its carboxy t e r m i n~s ,~.~ a short cytoplasmic domain (20 and 41 amino acids, respectively), and a much larger extracellular component.
The G P IIb-IIIa complex contributes to several platelet functions, most of which are acquired during platelet activation. For example, it acquires the ability to bind fibrinogen,6>' thereby mediating platelet aggregation during thrombus formation. In addition, G P IIb-IIIa is believed to mediate subsequent clot retraction by bridging the extracellular fibrin network to the contractile apparatus of the latel let.^,^ The complex also plays a role in signal transduction in stimulated platelets; for example, in tyrosine-specific protein phosphorylation" and in N a + / H + exchange across the plasma membrane." Furthermore, G P IIb-IIIa contributes to platelet adhesion to the subendothelium" and acts as a passive Ca2+ tran~p0rter.I~ Although G P IIb-IIIa has multiple functions, the mechanisms that regulate them are largely unknown. Since phosphorylation regulates the functions of other receptors, such as the @-adrenergic, insulin, and epidermal growth factor receptors (reviewed in reference 14) , we investigated whether any components of the G P IIb-IIIa complex are phosphorylated. The present study shows that G P IIIa is phosphorylated, primarily on threonine residues, and that the phosphorylation or turnover of phosphate increases dramatically in thrombin-or phorbol 12-myristate 13-acetate (PMA)-activated platelets. The agonist-induced phosphorylation is inhibited by prostacyclin (PGI,), an inhibitor of the intracellular events leading to platelet a~tivation.'~ In addition, evidence is provided that G P IIIa phosphorylation in platelets is catalyzed by protein kinase C (PKC). This study clearly implicates phosphorylation of G P IIIa as a potential fold in platelets activated with thrombin or phorbol 12-myristate 13-acetate, but not at all in platelets treated with prostacyclin, an inhibitor of platelet activation. The thrombin-induced increase in phosphorylation was inhibited by pretreating platelets with prostacyclin or with staurosporin, a specific protein kinase C inhibitor. Thus, there is an increase in the level or turnover of phosphate on GP llla during platelet activation, most likely involving protein kinase C. This phosphorylation may regulate some aspect(s) of GP Ilb-llla function.
0 1990 by The American Society of Hematology.
mechanism by which activation-induced changes in G P IIb-IIIa function could be regulated.
MATERIALS AND METHODS
Human platelets were obtained on the day of use and washed as previously described16 but in the absence of PGI, and EDTA, and were resuspended to 1 to 2 x lo9 platelets/mL in buffer A (12 mmol/L NaHCO,, 138 mmol/L NaCl, 5.5 mmol/L glucose, 2.9 mmol/L KCI, 10 mmol/L HEPES, pH 7.4). The platelet suspension was incubated with 1 mCi of H,[32P]04 (ICN Biomedicals, Inc, Irvine, CA)/mL of platelets at room temperature for 30 minutes, sedimented at 730g for 10 minutes, and resuspended to 0.7 to 0.8 x 10' platelets/mL in buffer A with 0.36 mmol/L NaH,P04 H,O. The platelets were then incubated at 37OC without stirring for the times and at the concentrations of agents indicated in the figure legends. The concentrations of agents were chosen on the basis of their ability to induce either maximal aggregative or inhibitory responses. The concentrations of PGI, were chosen according to their ability to inhibit platelet aggregation induced by 0.1 U of thrombin/mL. These concentrations varied with platelets from different donors and ranged from 60 to 370 nmol/L. The actual phosphorylation experiments with thrombin and PMA were done with activated, aggregation-competent platelets but without stirring and, therefore, without aggregation per se, so that GP IIb-IIIa could be quantitatively and reproducibly immunoprecipitated.
Immunoafinity chromatography. Approximately 1.2 x 1 O9 platelets were incubated at 37OC with platelet agonists, antagonists, or appropriate buffers, as indicated in the figure legends and text. The incubations were terminated by diluting the sample with an q u a l volume of icecold lysis buffer (2% Triton X-100. 20 
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A,A,-Scpharosc in 0.25 mL of the pH 11.3 elution buffer and recovering the supernatant. Phmphwmino acid analysis. Glycoprotein Ilb-llla was ilated by immunoaffinity chromatography a s described above. exthat I .5 to 2 x IO' lyscd platelets and a 0.8 to I mL A,A,-Sepharosc column were used. Approximately 2.4 mL of the immunoafinitypurified GP Ilb-llla was precipitated with trichloroacetic acid pH 6.81). and heated to loooC for 5 minutes.'" After electrophoresis on a preparative 7.5% gel. GP llla was electrocluted at 100 V for 3 hours into IS mmol/L ammonium carbonate and 0.1% SDS (wt/ vol). pH 8.2. To remove the SDS. the electroeluted protein was precipitated with IS volumes of I% (vol/vol) HCI in acetone at -20% for 2 hours. and the precipitated GP llla was pellcted by low-speed antrifugation. The pellet was washed in HCl/acetone and ramtrifuged. and the acetone-supernatant was discarded. The washed pellet was dissolved in 6 N HCI. sealed in vacuo. and hydrolytnd for 2 hours at I IOOC. The hydrolysates were dried over solid NaOH in vacuo. dissolved in 80 pL of electrophoresis buffer ( I % pyridine Ivol/vol]. 10% glacial a a t i c acid [vol/vol] . pH 3.5). and then electrophoresed along with phosphoserine. phosphothnw nine. and phosphotymine standards on Whatman / I chromatography paper for 1.25 hours at 3 kV in the electrophoresis buffer described above. The p i t i o n s of the standards were determined after staining with 0.2% ninhydrin (wt/vol) in acetone. and the "P-labeled amino acids were identified after autoradiography.
RESULTS
To determine whether GP Ilb or GP llla was phosphory- For (Fig   1) . The purified material was essentially homogeneous (Fig  1, lane 1) . Only one component of the complex was phosphorylated. This was identified as G P IIIa (lanes 2 and 4) on the basis of its co-electrophoresis with iodinated G P IIIa (lanes 3 and 5) from the purified G P IIb-IIIa complex.
The possibility that G P IIIa was phosphorylated only as a consequence of detergent lysis of platelets was eliminated by two experiments. First, "P-labeled platelets were lysed in the presence of excess unlabeled adenosine triphosphate ( A T P 0.5 mg/mL); the unlabeled ATP would be expected to inhibit phosphorylation of G P IIIa that might occur after lysis and the release of cytoplasmic [32P]ATP. No inhibition of G P IIIa phosphorylation by excess unlabeled ATP was observed (data not shown). Second, when unlabeled platelets were lysed in the presence of [32P]ATP, no phosphorylation of G P IIIa was observed (data not shown). Thus, phosphorylation occurs before lysis, most likely on the cytoplasmic domain of G P IIIa.
To determine whether G P IIIa underwent increased phosphorylation when platelets were activated, "P-labeled platelets were exposed to the agonists thrombin or PMA. Thrombin caused a 4.1-fold increase in G P IIIa phosphorylation within 3 minutes, followed by a steady decrease (Fig 2A) . The time course of G P IIIa phosphorylation was similar to other events that occur under similar conditions during platelet activation, eg, the expression of platelet fibrinogenbinding activity." Further, the fold-increase was comparable with that of other platelet proteins whose functions are regulated by phosphorylation (see Discussion). As shown in Fig 2B, PMA, an agent that directly activates PKC," caused an increase in G P IIIa phosphorylation similar to that induced by thrombin (4.3-fold over the control value a t 5 minutes). This was also followed by a decrease. The decrease in phosphorylation shown in Fig 2A and B was specific for G P IIIa; it did not occur with total precipitated phosphoproteins (data not shown). Therefore, the decrease probably represents a loss of phosphate from G P IIIa, rather than an exchange with unlabeled phosphate.
The changes in G P IIIa phosphorylation shown in Fig 2 were also apparent when G P IIIa phosphorylation was measured in separate experiments as the amount of '*P incorporated per milligram of G P IIIa. In those experiments, 32P-labeled platelets were treated for 3 minutes with thrombin or 5 minutes with PMA. After lysis, relatively large amounts of G P Ilb-IIIa were isolated from these platelets by immunoaffinity chromatography. The milligram amount of GP IIIa was quantitated from Coomassie-stained gels versus a standard curve of G P IIIa on the same gels, and the amount of 32P was quantitated by densitometry of G P IIIa on autoradiograms. When the results were expressed as the amount of 32P/mg of G P IIIa, we found that thrombin induced a 2.5-fold increase and PMA induced a 4.5-fold increase in G P IIIa phosphorylation relative to the control.
The responses of platelets to agonists are inhibited by agents such as PGI, that elevate cyclic adenosine monophosphate (AMP) levels within the cytosol. The basis for the inhibition is presumably related to the phosphorylation of certain platelet proteins by cyclic AMP-dependent protein kinase.,' When resting platelets were treated with PGI,, G P IIIa phosphorylation was not induced (Fig 2C) , suggesting that cyclic AMP-dependent protein kinase was not responsible for phosphorylating G P IIIa. In a separate experiment, PGI, did inhibit the thrombin-induced phosphorylation of GP IIIa, indicating that the agonist-induced phosphorylation is on the stimulus-response pathway of platelets. (In this experiment, pretreatment of platelets with PGI, (370 nmol/ L) for 1 minute before the addition of thrombin (0.1 U/mL) resulted in a 72% 7.5% (SE, n = 3) inhibition of the thrombin-induced increase.)
To determine which amino acid(s) was phosphorylated, 32P-labeled GP IIIa was electroeluted from a preparative SDS-gel, partially hydrolyzed with acid, and subjected to high-voltage paper electrophoresis under conditions that separated P-serine, P-threonine, and P-tyrosine. Regardless of whether platelets were treated with PMA, thrombin, or For personal use only. on October 3, 2017. by guest www.bloodjournal.org From b u l k (ie. control). threonine was observed to be the major "P-labcled amino acid residue (Fig 3) . A low level of serine phosphorylation was alsoobserved (Fig 3. lanes I and 3) . but no tyrosine phosphorylation was apparent.
Rccause PMA directly activates PKC and induces GP l l l a phosphorylation. we investigated whether this enzyme participated in the thrombin-induced phosphorylation of GP I1 la.
since thrombin is a physiologic platelet activator.'? I n thcsc experiments. platelets were pretreated with staurosprin. an inhibitor of PKC." The concentration of staurosprin ( I pmol/l.) used was a minimum value. selected because i t was just high enough to maximally inhibit the thrombin-induced phosphorylation of P47. a known substrate of PKC in platclcts" (Fig 4A) . Phosphorylation of P47 was inhibited under conditions in which many other platelet proteins remained phosphorylated. even at relatively high concentrations of staurosprin (Fig 4A. inset) . supporting the relative specificity of this inhibitor. This finding contrasts with results obtained with sphingosine. another inhibitor of PKC": at a concentration that minimally inhibited P47 phosphorylation. sphingosinecauscd the disappearance of many other phosphorylated bands in a total platelet lysate (data not shown).
When '-'P-labeled platelets were pretreated with staurosporin. the thrombin-induced phosphorylation of GP I 1 la was completely inhibited (Fig 4R) -cvidencc that PKC
phosphorylates GP I1 l a in thrombin-stimulated platelets.
DISCUSSION
This study shows that GP l l l a of the GP I l b -l l l a complex is phosphorylated. primarily on threonine residues. in intact human platelets. Activation of platelets with the physiologic agonist thrombin dramatically increases this phosphoryla- platelets that is reported t o stabilize this protein against calpain hydrolysis": a n d t h e 1.4-fold increase in GP Ib, phosphorylation that inhibits actin polymerization.'' Third. agonist-induced phosphorylation was inhibited by PGI,. a n agent t h a t also inhibits agonist-induced changes in platelet function.
W h e n platelets a r e activated. GP I l b -l l l a is converted from a form that cannot bind extracellular fibrinogen into a form that can." In addition, undefined activation-induced events cause t h e intracellular domain of t h e G P Ilb-llla of these changes in t h e function of GP I l b -l l l a is exemplified by Glanzmann's thrombasthenia. a hereditary bleeding disorder. PhtClCtS from these patients have either lOW amOUntS Of or functionally abnormal GP Ilb-llla,'x~'" resulting in t h e absence of agonist-induced platelet aggregation o r clot r e traction. Despite t h e importance of agonist-induced changes in GP Ilb-llla, very little is known about t h e intracellular mechanisms that regulate them. The present study shows an activation-induced chemical modification of GP llbllla. Further studies are necessary t o assess t h e consequence of GP llla phosphorylation on t h e numerous functions associated with GP llb-llla. 
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